Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M

Ceribell, Inc.

2026-Q1 EPS reported -$0.52 vs consensus -$0.40 ▼ miss (-30.7%)

Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.
Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.
Launched neonate/pediatric EEG products; 680 active accounts at quarter end.
CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.
FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ceribell, Inc. reported first quarter ended March 31, 2026 results: revenue $26.5 million, net income $19.7 million, EPS $0.52 net loss per share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $26.5 million
Net income: $19.7 million
EPS: $0.52 net loss per share
Guidance: raised
Result: reported results

Exact text from the filing

serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights • Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025 • Ended the quarter with 680 total active accounts • Achieved gross margin of 87% • Initiated

View on SEC.gov

Browse all earnings releases →

Ceribell, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.